Syschem (India) Ltd
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.[1]
- Market Cap ₹ 172 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 62.0 / 29.3
- Stock P/E 28.0
- Book Value ₹ 25.0
- Dividend Yield 0.00 %
- ROCE 15.9 %
- ROE 10.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 32.4% CAGR over last 5 years
- Promoter holding has increased by 2.52% over last quarter.
- Company's median sales growth is 70.0% of last 10 years
- Company's working capital requirements have reduced from 40.8 days to 29.3 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.41% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11 | 4 | 13 | 67 | 93 | 77 | 68 | 59 | 114 | 199 | 332 | 574 | 574 | |
| 14 | 5 | 12 | 63 | 89 | 77 | 73 | 58 | 105 | 192 | 328 | 553 | 554 | |
| Operating Profit | -3 | -1 | 0 | 3 | 4 | -0 | -5 | 1 | 9 | 7 | 4 | 21 | 19 |
| OPM % | -23% | -24% | 0.4% | 4.5% | 4.4% | -0.1% | -7% | 0.9% | 8% | 3.5% | 1.2% | 3.7% | 3.3% |
| 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 5 |
| Profit before tax | -5 | -3 | -2 | 1 | 2 | -2 | -7 | -2 | 6 | 4 | 1 | 15 | 12 |
| Tax % | -26% | -27% | -30% | 43% | 50% | -16% | -24% | -22% | 27% | 33% | 54% | 26% | |
| -4 | -2 | -1 | 0 | 1 | -2 | -6 | -2 | 5 | 3 | 0 | 11 | 6 | |
| EPS in Rs | -1.94 | -1.13 | -0.75 | 0.17 | 0.32 | -0.79 | -2.07 | -0.59 | 1.13 | 0.69 | 0.11 | 2.23 | 1.42 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 66% |
| 5 Years: | 53% |
| 3 Years: | 72% |
| TTM: | 62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 32% |
| 3 Years: | 34% |
| TTM: | 209% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 34% |
| 3 Years: | -12% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| Last Year: | 10% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 22 | 23 | 32 | 40 | 44 | 49 |
| Reserves | -6 | -8 | -10 | -8 | -8 | -10 | -15 | -16 | -10 | 17 | 48 | 73 |
| 28 | 27 | 22 | 20 | 16 | 17 | 16 | 2 | 2 | 0 | 0 | 0 | |
| 13 | 12 | 16 | 29 | 35 | 36 | 55 | 51 | 69 | 107 | 126 | 169 | |
| Total Liabilities | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
| 34 | 32 | 30 | 29 | 27 | 28 | 30 | 32 | 31 | 31 | 53 | 68 | |
| CWIP | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | 15 | 14 | 28 | 35 | 34 | 46 | 28 | 62 | 129 | 164 | 224 | |
| Total Assets | 51 | 47 | 44 | 58 | 62 | 62 | 77 | 60 | 93 | 164 | 217 | 292 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 6 | 0 | -2 | 3 | 4 | 1 | -8 | -26 | -10 | 8 | |
| 0 | 0 | 0 | 0 | 2 | -4 | -4 | -1 | -2 | -6 | -22 | -20 | |
| -2 | -1 | -7 | -0 | -0 | -0 | -0 | -0 | 11 | 32 | 34 | 18 | |
| Net Cash Flow | -1 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 1 | -0 | 2 | 6 |
| Free Cash Flow | 1 | 0 | 6 | -1 | -2 | 0 | -1 | -2 | -10 | -32 | -32 | -11 |
| CFO/OP | -56% | -53% | 12,760% | 9% | -24% | -3,456% | -40% | 107% | -79% | -348% | -238% | 54% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 187 | 272 | 124 | 47 | 21 | 47 | 31 | 21 | 135 | 126 | 99 | 92 |
| Inventory Days | 228 | 868 | 182 | 80 | 104 | 110 | 199 | 152 | 61 | 107 | 81 | 41 |
| Days Payable | 290 | 870 | 424 | 151 | 131 | 175 | 221 | 186 | 158 | 198 | 143 | 112 |
| Cash Conversion Cycle | 124 | 271 | -119 | -24 | -7 | -19 | 9 | -14 | 38 | 34 | 36 | 21 |
| Working Capital Days | -139 | -564 | -319 | -50 | -20 | -36 | -1 | -15 | 48 | 54 | 39 | 29 |
| ROCE % | -11% | -8% | -6% | 3% | 7% | -8% | -29% | -12% | 38% | 11% | 1% | 16% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Permanent Employees count |
|
||||||||||
| Installed Production Capacity TPA |
|||||||||||
| Production Volume MT |
|||||||||||
| Export Sales as % of Total Revenue % |
|||||||||||
| Number of Export Countries count |
|||||||||||
| Number of Customers (Consumers and Traders) count |
|||||||||||
Extracted by Screener AI
Documents
Announcements
- General Update_ Clarification On Investor Presentation
- Investor Presentation
-
Newspaper Advertisements
- Syschem published Q1 FY2026-27 unaudited results newspapers on 5 August 2026.
-
Clarification In Regards To The Lapse Of Share Warrants Uploaded On 04.08.2026 As Per Regulation 30 Of SEBI(LODR), 2015
- 31,97,500 of 1,67,00,000 warrants lapsed; remaining warrants converted into equity shares.
-
Board Meeting Outcome for Outcome Of Board Meeting
- Syschem approved Q1 FY27 results; 1.67 crore warrants lapsed on 3 Aug 2026, forfeiting Rs 3.92 crore.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Product Profile:[1]
API/ Intermediates:
** a) Amoxycillin Trihydrate
b) Ampicillin Trihydrate
c) Cloxacillin Sodium
d) Dicloxacillin Sodium
e) Flucloxacillin Sodium (For export only)
f) Cephalexin
g) Cefadroxil
h) **Distillation of Specialist Solvents – methonel, Acetonitrile, Ethyl Acetate, and THF